1 / 9

The FRET Study

The FRET Study. Source: Inoue T, Ikeda H, Nakamura T, et al . Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET). Intern Med . 2011;50(12):1273–1278. Background:

fallon-waller
Download Presentation

The FRET Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The FRET Study Source: Inoue T, Ikeda H, Nakamura T, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET). Intern Med. 2011;50(12):1273–1278.

  2. Background: Morbidity and mortality related to cardiovascular disease in chronic kidney disease (CKD) patients is also attributed to dyslipidemia and managing the same is crucial.

  3. Aim: To determine whether fluvastatin, which is mostly characterized by its pleiotropic anti-oxidant effects, has renoprotective effects in dyslipidemic patients with CKD.

  4. Methods: • Number of patients: 43 dyslipidemic patients with CKD. • Intervention: 10, 20 or 30 mg/day fluvastatin. • In the study, the renal functions as well as lipid profiles were assessed.

  5. Results: • With fluvastatin, there was a significant reduction in the levels of LDL (after 3 months). • No change in the serum creatinine level, estimated glomerular filtration rate (eGFR), urinary albumin excretion (UAE), urinary liver-type fatty-acid-binding protein (L-FABP) level and urinary 8-hydroxydeoxyguanosine (8-OHdG) level in overall patients. • Significant decrease in the UAE was observed in patients with microalbuminuria (baseline UAE ≥30 mg/g·creatinine; n=23) [from 2.43±0.67 to 1.98±0.80 log(mg/g·creatinine), p=0.01]. • There was a significant decrease in the urinary L-FABP levels (from 1.52±0.45 to 1.26±0.43 µg/g. creatinine, p<0.01). • Also, the 8-OHdG level was significantly decreased (from 13.6±9.6 to 9.8±3.8 ng/g. creatinine, p=0.043).

  6. Conclusion: Fluvastatin, besides lowering lipids, reduces UAE and the urinary L-FABP level. These pleiotropic benefits offer renoprotective effects in dyslipidemic patients with CKD.

More Related